Delivery Order SPE2DB20D1100-SPE2DB25FA4H5

Award Date 2/4/25
Potential Completion Date 2/5/25
Potential Value $1.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award from the Defense Logistics Agency (DLA) was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,364.70 firm fixed-price delivery order is for Mycophenolate 500 mg tablets, a specialty medication. The contract has a ceiling value of $1,364.70 and an ultimate completion date of February 12, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical that...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,379.40, is for the delivery of 4,564,886 units of the pharmaceutical drug Mycophenolate 500 mg tablets. The contract has a completion date of June 13, 2024 and is a firm fixed-price contract. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The award, a firm fixed price delivery order, is for the supply of Mycophenolate 500 mg tablets. The contract has a ceiling value of $2,073.55 and a period of performance through April 3, 2024. Amerisourcebergen Drug Corp is the prime contractor and holds an...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,331.60, is for the delivery of Mycophenolate 500 mg tablets. The contract is a firm fixed-price delivery order and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a firm fixed price delivery order contract worth $3,066.66 by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of MYCOPHENOLATE 500 MG TABLET 500S, a pharmaceutical product, with a completion date of January 26, 2024. This delivery order is issued under an indefinite delivery contract (IDC) with a potential value of $999,999,999.00 and a performance period through...
This contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) to provide MYCOPHENOLIC ACID DR 360 MG TB 120S, a pharmaceutical product. The $1,246.77 firm fixed-price delivery order has a completion date of January 23, 2025 and is not designated as a set-aside contract. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to supply a comprehensive range of...
This federal contract award, valued at $8,456.08, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Mycophenolate 200 mg/ml suspension, a specialty medication, to support federal healthcare programs. The award is associated with a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award, valued at $4,966.48, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of MYCOPHENOLATE 200 MG/ML SUSP 160ML, a pharmaceutical product, to support military healthcare programs. The contract is structured as a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical,...
This federal contract award, valued at $1,052.29, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of pharmaceutical products and medical supplies to support military healthcare programs. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical. This IDC serves as...
This federal contract award, valued at $1,313.49, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of a variety of pharmaceutical products and medical supplies. The contract is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a potential value of up to $999,999,999.00 and runs through November 2026. This IDC serves as the primary vehicle for...
  • SPE2DB20D1100
    Indefinite Delivery Contract
  • SPE2DB20D1100-SPE2DB25FA4H5
    Delivery Order

This federal contract award, valued at $1,124.48, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of MYCOPHENOLATE 500 MG TABLET 500S, a pharmaceutical product, and does not have a set-aside designation.

Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. In addition, the company maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.

Generated 5/21/25, 10:06 AM